€6 million for innovative wound care from Plasmacure
The Nijmegen-based medtech company Plasmacure today announced an investment of €6 million.
Published on July 7, 2025
Team IO+ selects and features the most important news stories on innovation and technology, carefully curated by our editors.
The Nijmegen-based medtech company Plasmacure today announced an investment of €6 million. By using cold plasma, their solution can heal up to two and a half times more wounds than standard wound care. The financing round is led by the American company Venture Medical, LLC. This party is also investing more than $10 million in admission to the US market.
The investment consortium also includes Dutch health insurer Coöperatie VGZ, impact investor Noaber, Stichting Triade, and existing shareholders EIC Fund and Oost NL. This investment will enable Plasmacure to scale up to international markets and roll out PLASOMA as an innovative solution for closing complex wounds, such as those caused by diabetes and pressure ulcers.
More people with complex wounds
The global population is aging and the number of people with diabetes is rising. As a result, an estimated 5% of older people suffer from complex wounds. These wounds have a major impact on daily functioning and, in severe cases, can lead to amputations. Current treatments often provide insufficient results, causing wounds to become chronic. This entails considerable healthcare costs — estimated at 2 to 4% of total healthcare expenditure.
2.5 times more effective
Recent research shows that PLASOMA technology is up to 2.5 times more effective in closing wounds than standard care. PLASOMA uses cold plasma, which is generated by activating gas molecules with electrical energy. This creates a powerful antimicrobial effect that even works against bacteria that are resistant to antibiotics.
The technology uses a pulser that emits controlled electrical pulses to a disposable pad, which generates the cold plasma directly in the wound. This safely stimulates multiple processes that promote healing and reduces the negative effects of long-term wounds.
‘Transforming wound care’
“We are motivated by the demand from millions of people with difficult-to-heal wounds,” says Bjorn Sprengers, CEO of Plasmacure. "Thanks to this investment and the collaboration with new strategic partners, we can make PLASOMA available worldwide. Our vision is to transform wound care, not only to improve treatment outcomes, but to give patients back their mobility, dignity, and freedom. With PLASOMA, we want to set the global standard in the treatment of complex wounds."
Plasmacure is a former winner of the Gerard & Anton Awards: the annual selection of the ten most promising startups in the Brainport Eindhoven region.
